German-Austrian recommendations for HIV-therapy in pregnancy and in HIV-exposed newborn - Update 2005

European Journal of Medical Research

Volumn 11, Issue 9, 2006, Pages 359-376

  Buchholz, Bernd ^a   Beichert, Matthias ^b   Marcus, Ulrich ^c   Grubert, Thomas ^d   Gingelmaier, Andrea ^d   Haberl, Annette ^e   Schmied, Brigitte ^f   Brockmeyer, Norbert ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Gynecology and Obstetrics Practice ^*  (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f Otto Wagner Spital   (Austria)

Author keywords

Anti retroviral drugs; HIV status; HIV testing; HIV therapy; Pregnancy; Recommendations

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ARTICLE; AUSTRIA; BREAST FEEDING; CANCER; CARCINOGENICITY; CESAREAN SECTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FETOTOXICITY; FETUS ECHOGRAPHY; GENOTOXICITY; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LABORATORY TEST; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL RESEARCH; MEDICAL SPECIALIST; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEWBORN; NEWBORN CARE; NONHUMAN; PRACTICE GUIDELINE; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PREVENTIVE HEALTH SERVICE; RETREATMENT; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; AUSTRIA; DISEASE TRANSMISSION, VERTICAL; FEMALE; GERMANY; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE;

EID: 33750064539     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (134)

1. Bundeszentrale für gesundheitliche Aufklärung, Köln: Aids von A bis Z; Neuauflage 2002
2. Deutsche AIDS-Hilfe e.V.: Der heutige Wissensstand 28. überarbeitete Auflage, 2002
3. Mayaux MJ, Dussaix E, Isopet J et al.: Maternal Virus Load during Pregnancy and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1: The French Perinatal Cohort Studies. J Infect Dis 1997; 175: 172-175
4. Sperling RS, Shapiro DE, Coombs RW et al.: Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. N Engl J Med 1996; 335: 1621-1629
5. Cooper ER, Charurat M, Mofenson L et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. JAIDS 2002; 29: 484-494
6. Poirier MC, Divi RL, Al-Harthi L et al.: Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. JAIDS 2003; 32: 175-183
7. Barret B, Tardieu M, Rustin P et al.: Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769-1785
8. Blanche S, Tardieu M, Rustin P et al.: Persistent mitochondrial dysfunction and perinatal exposure to anti-retroviral nucleoside analogues. Lancet 1999; 354: 1084-1089
9. Poirier MC, Patterson TA, Slikker Jr. W, Olivero OA: Incorporation of 3′-Azido-3′-Deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. JAIDS 1999; 22: 477-483
10. Meng Q, Walker DM, Olivero OA et al.: Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 2000; 97: 12667-12671
11. Scalfaro P, Chesaux JJ, Buchwalder PA et al.: Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998; 24: 247-250
12. European Collaborative Study: Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. JAIDS 2003; 32: 380-387
13. Wahn V: Routinemäßige Gabe von Zidovudin an HIV-infizierte Schwangere. Dt Ärztebl 1995; 92:A-3397-3398
14. Frenkel LM, Cowles MK, Shapiro DE et al.: Analysis of the Maternal Components of the AIDS Clinical Trial Group 076 Zidovudine Regimen in the Prevention of Mother-to-Infant Transmission of Human Immunodeficiency Virus Type 1. J Infect Dis 1997; 175: 971-974
15. Landesmann SH, Kalish LA, Burns DN et al.: Obstetrical Factors and The Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child. N Engl J Med 1996; 334:1617-1623
16. Mandelbrot L, Le Chenadec J, Berrebi A et al.: Perinatal HIV-1 Transmission. Interaction between Zidovudine Prophylaxis and Mode of Delivery in the French Perinatal Cohort. JAMA 1998; 280: 55-60
17. Pitt J, Brambilla D, Reichelderfer P et al.: Maternal Immunologic and Virologic Risk Factors for Infant Human Immunodeficiency Virus Type 1 Infection: Findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175: 567-575
18. Rokos K, Wang H, Seeger J et al.: Transport of Viruses Through Fetal Membranes: An In Vitro Model of Perinatal Transmission. J Med Virology 1998; 54: 313-319
19. The European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996; 10: 1675-1681
20. The European Collaborative Study: Immunological markers in HIV-infected pregnant women. AIDS 1997; 11: 1859-1865
21. Tuomala RE, O'Driscoll PT, Bremer JW et al.: Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. JID 2003; 187: 375-384
22. Burns DN, Landesman S, Wright, DJ et al.: Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175:1206-1210
23. Gaillard P, Verhofstede C, Mwanyumba F et al.: Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS 2000; 14: 2341-2348
24. Wright TC Jr, Subbarao S, Ellerbrock TV et al.: Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001; 184: 279-285
25. Mwanyumba F, Gaillard P, Inion I et al.: Placental inflammation and perinatal transmission of HIV-1. JAIDS 2002; 29: 262-269
26. Kind Ch, Rudin Ch, Siegrist C et al.: Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205-210
27. Schäfer APA: Die HIV-Infektion in Geburtshilfe und Gynäkologie. Gynäkologe 1996; 29:129-137
28. Schäfer A, Friese K, Lauper U et al.: Influence of cesarean section before parturition and antiretroviral prophylaxis on the materno-fetal transmission of HIV. 12th World AIDS Conference Geneva, June 28-July 3 1998, Poster LB 12466
29. Salzberger B, Marcus U, Vielhaber B et al.: German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res. 2004; 9(11): 491-504 URL: http:// www.daignet.de unter Leithnien
30. Coll O, Fiore S, Floridia M et al.: Pregnancy and HIV infection: A european consensus on management. AIDS 2002; 16 (Suppl 2): S1-18
31. CDC Public Health Service Task Force: Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR 1998; 47/RR2
32. CDC: Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. MMWR 1998; 47/RR-5
33. Justman JE, Benning L, Danoff A et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS 2003; 32: 298-302
34. Lorenzi P, Spicher VM, Laubereau B et al. (Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study): Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12 (18): F 241-247
35. Wimalasundera RC, Larbalestier N, Smith JH et al.: Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002, 360: 1152-1154
36. Tuomala RE, Shapiro DE, Mofenson LM et al.: Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870
37. Conley LJ, Ellerbrock TV, Bush TJ et al.: HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359: 108-113
38. Vandamme AM, Sonnerborg A, Ait-Khaled M et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9(6): 829-848
39. Welles SL, Pitt J, Colgrove R and The Women and Infants Transmission Study Group: HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000; 14:263-271
40. Duwe S, Brunn M, Altmann D et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. JAIDS 2001; 26: 266-273
41. Eastman PS, Shapiro DE, Coombs RW et al.: Maternal Viral Genotypic Zidovudine Resistance and Infrequent Zidovudine Therapy to Prevent Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Pediatric Clinical Trial Protocol 076. J Infect Dis 1998; 177: 557-564
42. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al.: Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-2093
43. Jackson JB, Becker-Pergola G, Guay LA et al.: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111-F115
44. Eshleman SH, Hoover DR, Chen S et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192(1): 30-36
45. Sustiva Capsules Product Monograph 1998
46. BMS Warning Letter, 5. January 2001
47. Rich KC, Siegel JN, Jennings C et al.: CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis 1995; 172: 1221-1227
48. Kosel BW, Beckerman KP, Hayashi S et al.: Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17:1195-1199
49. Mirochnick M, Fenton T, Gagnier P et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-374
50. Wang Y, Livingston E, Patil S, et al.: Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180: 1536-1541
51. Qian M, Bui T, Ho RJY et al.: Metabolism of 3′-Azido-3′-Deoxythymidine (AZT) in Human Placental Trophophlasts and Hofbauer Cells. Biochemical Pharmacology 1994; 48: 383-389
52. Agbaria R, Manor E, Barak J et al.: Phosphorylation of 3′-Azidothymidine in maternal and fetal peripheral blood mononuclear cells during gestation and and at term. JAIDS 2003; 32: 477-481
53. Taylor GP, Lyall EGH, Back D et al.: Pharmacological implications of lengthened in-utero exposure to nevirapine. Lancet 2000; 355: 2134-2135
54. Marzolini C, Rudin C, Decosterd LA et al.: Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16: 889-893
55. Mirochnick M, Dorenbaum A, Holland D et al.: Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21 (9): 835-838
56. Mirochnick M, Dorenbaum A, Blanchard S et al.: Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. JAIDS 2003; 33(2): 153-156
57. Antiretroviral Pregnancy Registry Steering Committee: Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2005; Issued June 2005 Vol.13, No.1. Wilmington,NC: Registry Coordinating Center, 2004
58. Larsen WJ: Human Embryology. New York: Churchill Livingstone, 1993
59. Wilson JD, Frazer FC (Hrsg.): Handbook of Teratology, Vol. I. New York: Plenum Press, 1977
60. Spielmann H, Steinhoff R, Schaefer C et al.: Arzneiverordnung in Schwangerschaft und Stillzeit. 5. Aufl., Stuttgart, Gustav Fischer, 1998
61. Connor EM, Sperling RS, Gelber R et al.: Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment. N Engl J Med 1994; 331:1173-1180
62. Chuachoowong R, Shaffer N, Siriwasin W et al.: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Inf Dis 2000; 181: 99-106
63. Lallemant M, Jourdain G, Le Coeur S et al.: A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Eng J Med 2000; 343: 982-991
64. Wade NA, Birkhead GS, Warren BL et al.: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409-1414
65. Mbori-Ngacha D, Richardson BA, Overbaugh J et al.: Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. J Virol 2003; 77: 7702-7705
66. Ekpini RA, Nkengasong JN, Sibailly T et al.: Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002; 16: 625-630
67. Eastman PS, Shapiro DE, Coombs RW et al.: Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177:557-564
68. Bardeguez AD, Shapiro DE, Mofenson LM et al.: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. JAIDS 2003; 32: 170-181
69. Clarke JR, Braganza R, Mirza A et al.: Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999; 59:364-368
70. O'Sullivan M, Boyer P, Scott G et al.: The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993; 168: 1510-1516
71. Garcia PM, Kalish LA, Pitt J et al.: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Eng J Med 1999; 341: 394-402
72. Mofenson LM, Lambert JS, Stiehm ER et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Eng J Med 1999; 341: 385-393
73. The European Collaborative Study: Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377-85
74. Shaffer N, Roongpisuthipong A, Siriwasin W et al.: Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Inf Dis 1999; 179: 590-599
75. Semprini AE: An international randomised trial of mode of delivery in HIV infected women. 12th World AIDS Conference Geneva, June 28-July 3 1998, Poster LB 23599
76. The International Perinatal HIV Group: The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Eng J Med 1999; 340: 977-987
77. CDC: Recommendations of the U-S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994; 43/RR-11
78. Grosch-Wörner I, Schäfer A, Obladen M et al.: An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. AIDS 2000; 14: 2903-2911
79. Burns DN, Landesman S, Muenz LR et al.: Cigarette smoking, premature rupture of membranes and vertical transmission of HIV1 among women with low CD4+ levels. JAIDS 1994; 7: 718-726
80. Mirochnick M, Dorenbaum A, Blanchard S et al.: Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: Association with timing of maternal intrapartum nevirapine dose. JAIDS 2003; 33: 153-156
81. Stringer JSA, Sinkala M, Chapman V et al.: Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003; 17: 1659-1665
82. Taha TE, Kumwenda NI, Hoover DR et al.: Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292(2): 202-209
83. Lallemant M, Jourdain G, Le Coeur S et al. Perinatal HIV Prevention Trial (Thailand) Investigators: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004; 351(3): 217-228
84. Dabis F, Bequet L, Ekouevi DK et al.: ANRS 1201/1202 DITRAME PLUS Study Group: Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19(3): 309-318.
85. Garcia-Tejedor A, Perales A, Maiques V: Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet. 2003; 82(1): 17-23.
86. Deutsch-Österreichische Empfehlungen zur postexpositionellen Prophylaxe nach HIV-Exposition (September 2004) URL: http://www.rki.de
87. Guay LA, Musoke P, Fleming T et al: Intrapartum and neonatal single dose nevirapine compares with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. HIVNET 012 randomized trial. Lancet 1999; 354: 795-802
88. Moodley D, Moodley J, Coovadia H et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-735
89. Flys T, Nissley DV, Claasen CW et al.: Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192(1): 24-29
90. Marcus U: AIDS und HIV-Infektionen bei Frauen und Kindern in Deutschland. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 1999; 42: 553-557
91. Shapiro D, Tuomala R, Samelson R et al. Abstract 12953, 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002
92. Ioannidis JPA, Abrams EJ, Ammann A et al.: CM: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000copies/ml. J Inf Dis 2001; 183: 539-545
93. Mandelbrot L, Burgard M, Teglas J-P et al.: Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999; 13: 2143-2149
94. Debiaggi M, Zara F, Spinillo A et al.: Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Microbiol Infect Dis 2001; 20: 91-96
95. Ellerbrock TV, Lennox JL, Clancy KA et al.: Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001, 184: 28-36
96. Si-Mohamed A, Kazatchkine MD, Goujon C et al.: Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000, 182: 112-122
97. Avidan MS, Groves P, Blott M et al.: Low complication rate associated with cesarean section under spinal anesthesia for HIV-1-infected women on antiretroviral therapy. Anesthesiology 2002; 97(2): 320-324
98. Read J, Tuomala R, Kpamegan E et al.: Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. JAIDS 2001; 26: 236-245
99. Rodriguez EJ, Spann C, Jamieson D et al.: Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am J Obstet Gynecol 2001, 184:1108-1111
100. Watts DH, Lambert JS, Stiehm ER et al.: Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. Am J Obstet Gynecol 2000; 183:100-107
101. European Collaborative Study and the Swiss Mother + Child HIV Cohort Study: Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-2920
102. Nduati R, John G, Mbori-Ngacha D et al.: Effect of breastfeeding and formula feeding on Transmission of HIV-1. JAMA 2000; 283: 1167-1174
103. Van de Perre P.: Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented? J Infect Dis. 1999; 179 Suppl 3: S405-407
104. Nduati RW, John GC, Richardson BA et al.: Human immunodeficiency virus type 1 infected cells in breast milk. Infect Dis 1995; 172: 1461-1468
105. Thiry L, Spencer-Goldberger S, Jonckheer T et al.: Isolation of AIDS virus from cell-free breastmilk of three healthy virus carriers. Lancet 1985 ii: 891-892
106. Haas J, Geiss M, Böhler T et al.: False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus type 1 in children infected with HIV strains of African origin. J Infect Dis 1996; 174: 224-225
107. Rossi P, et al.: Early diagnosis of HIV infection in infants - Report of a consensus workshop, Siena, Italy, January 17-18, 1992. JAIDS 1992; 5: 1168-1178
108. CENTERS OF DISEASE CONTROL: Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998; 47: 1-43; URL http:// www.hivatis.org
109. Capparelli EV, Mirochnick M, Dankner WM et al.: Pediatric AIDS Clinical Trials Group 331 Investigators: Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142(1): 47- 52
110. Maiques V, Garcia-Tejedor A, Perales A et al: HlV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol 2003; 108(2): 137-141
111. Davies G, Wilson RD, Desilets V et al.: Society of Obstetricians and Gynaecologists of Canada: Amniocentesis and women with hepatitis B, hepatitis C or human immunodeficiency virus. J Obstet Gynaecol Can 2003; 25(2): 145-148, 149-152
112. Poirier MC, Olivero CA, Walker DM et al.: Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199(2): 151-161
113. Mirochnick M, Capparelli E et al.: Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43(15): 1071-1087
114. Lyons FE, Coughlan S, Byrne CM et al.: Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19(1): 63-67
115. Nolan M, Fowler MG, Molenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr. 2002; 30(2): 216-29. Review
116. Thorne C, Patel D, Newell ML: Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18(17): 2337-2339
117. Fiore S, Newell ML, Thorne C: European HIV in Obstetrics Group: Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004; 18(6): 933-938
118. Marcollet A, Goffinet F, Firtion G et al: Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002; 186(4): 784-789
119. Kovacs A, Wasserman SS, Burns D et al.: DATRI Study Group; WIHS Study Group: Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358(9293): 1593-1601
120. Fiore JR, Suligoi B, Saracino A et al.: Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17(15): 2169-2176
121. Tuomala RE, O'Driscoll PT, Bremer JW et al.: Women and Infants Transmission Study: Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003; 187(3): 375-384
122. Chaix ML, Dabis F, Ekouevi D et al.: Addition of 3 Days of ZDV+3TC Postpartum to a Short Course of ZDV+3TC and Single-dose NVP Provides Low Rate of NVP Resistance Mutations and High Efficacy in Preventing Peri-partum HIV-1 Transmission: ANRS DITRAME Plus, Abidjan, Côte d'Ivoire. 12th CROI, Boston 2005, Abstr. 72LB
123. Mofenson LM, Lambert JS, Stiehm ER et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999; 341(6): 385-393
124. Ioannidis JP, Contopoulos-Ioannidis DG: Maternal viral load and the risk of perinatal transmission of HIV-1. N Engl J Med. 1999; 341(22): 1698-1700
125. Chappuy H, Treluyer JM, Rey E et al.: Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004; 191(2): 558-562
126. Feiterna-Sperling C, Piening T, Casteleyn S: Use of lopinavir (LPV/r) during pregnancy Eur J Med Res 10 Supplement 11, S. 89 P161.
127. Meyohas MC, Lacombe K, Carbonne B et al.: Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS 2004; 18(14): 1966-1968
128. Morris A, Juethner S, Theroux E: Atazanavir use in pregnancy. Third International AIDS Society Conference on HIV Pathogenesis and Therapy, Rio, poster presentation TuPe5.2p01, 2005.
129. Dunn DT, Brandt CD, Kirvine A et al.: The sensitivity of HIV1-DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995; 9(9): F7-11
130. Chaisilwattana P, Chokephaibulkit K, Chalermchockcharoenkit A et al.: Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 2002 35(11): 1405-1413
131. European collaborative study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001 15(6): 761-770
132. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 40(3): 458-465
133. Ananworanich J, Siangphoe U, Hill A et al.: Highly active antiretroviral therapy (HAARI) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. JAIDS 2005; 39(5): 523-529
134. Pellegrin I, Thiebaut R, Blanco P et al.: Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4(+) cells/microl? Impact on immunovirological parameters. J Med Virol 2005; 77(2): 164-172